neuregulin-4 (NRG-4) / Avexegen Therap - LARVOL DELTA

Avexegen Therapeutics Receives a $2.94M NIH Grant to Advance Treatment for Inflammatory Bowel Disease (PRNewswire) - "Avexegen Therapeutics Inc. today announced that it has received a Phase 2 award of $2.94 million under the National Institutes of Health's Small Business Innovation Research Program (SBIR) for the development of an oral Neuregulin-4-based therapy for inflammatory bowel disease (IBD)."

Financing • Immunology • Inflammatory Bowel Disease